What is Ozempic face and why are patients seeking treatment for it?

Ozempic face refers to the hollowed, gaunt appearance that can result from rapid weight loss on GLP-1 drugs like semaglutide and tirzepatide. Patients are seeking facial rejuvenation treatments to address volume loss, skin laxity, and facial hollowing caused by these medications.

Which injectables are most in demand from GLP-1 patients?

Neuromodulators and volumizing fillers are seeing the highest demand from this demographic. Practices should prioritize robust inventory of hyaluronic acid (HA) fillers and biostimulators to meet the increased treatment frequency in this patient segment.

How should practices adjust their protocols for GLP-1 weight loss patients?

Practices should develop combination protocols that address both dynamic lines and structural volume loss, requiring trained staff to counsel patients on integrated treatment plans. This approach capitalizes on the elevated per-patient treatment frequency observed in weight-loss-conscious demographics.

What GLP-1 drugs are driving the demand for facial aesthetics?

Semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Zepbound and Mounjaro) are the primary drivers of this trend. As patients on these medications experience significant weight loss, they're seeking facial rejuvenation services.

Is the GLP-1 trend boosting revenue for aesthetic companies like Galderma?

Yes—Galderma reported record H1 performance partly fueled by increased demand for injectables from GLP-1 patients. This demographic shift is driving incremental injectable volume and higher per-patient treatment frequency for practices positioned to serve this market.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Market

Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know

Rising demand for facial rejuvenation among patients on semaglutide and tirzepatide is driving injectable volume.

By Evan at Inside MedSpa · Jul 26, 2026

Galderma's record H1 performance is partly fueled by an unexpected tailwind: the GLP-1 weight loss drug boom. As patients on semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) shed pounds, many are seeking facial rejuvenation to address volume loss, skin laxity, and the hollowed appearance colloquially known as "Ozempic face."

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/galderma-glp-1-weight-loss-trend-revenue-boost/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know

Share

Discussion

Leave a comment

By the time it's news, it's too late.